Compare GCT & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GCT | COAG |
|---|---|---|
| Founded | 2019 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2021 | 2026 |
| Metric | GCT | COAG |
|---|---|---|
| Price | $33.37 | $28.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $33.00 | N/A |
| AVG Volume (30 Days) | ★ 688.9K | 319.5K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.70 | N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $1,161,042,000.00 | N/A |
| Revenue This Year | $14.43 | N/A |
| Revenue Next Year | $6.78 | N/A |
| P/E Ratio | $32.03 | ★ N/A |
| Revenue Growth | ★ 64.96 | N/A |
| 52 Week Low | $19.25 | $27.83 |
| 52 Week High | $51.82 | $31.98 |
| Indicator | GCT | COAG |
|---|---|---|
| Relative Strength Index (RSI) | 41.46 | N/A |
| Support Level | $25.96 | N/A |
| Resistance Level | $34.46 | N/A |
| Average True Range (ATR) | 1.49 | 0.00 |
| MACD | 0.33 | 0.00 |
| Stochastic Oscillator | 42.45 | 0.00 |
GigaCloud Technology Inc provides end-to-end and B2B e-commerce solutions for large parcel merchandise. Its B2B e-commerce platform, which is referred to as the GigaCloud Marketplace, integrates everything from discovery, payments, and logistics tools into one easy-to-use platform. It offers online and offline integrated cross-border transaction and delivery services for furniture and large merchandise. Its marketplace seamlessly connects manufacturers in Asia with resellers in the U.S., Asia, and Europe to execute cross-border transactions with confidence, speed, and efficiency. It offers a truly comprehensive solution that transports products from the manufacturer's warehouse to end customers, all at one fixed price. It earns the majority of its revenue from the United States.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.